CD8A and neoplasm: Transduction of fusion-type IGKV3-20 by mDCs efficiently induces CD4+ and CD8+ CTL responses, and these CTLs are able to kill autologous mother cells expressing IGKV3-20 or pulsed IGKV3-20-synthesized peptides or HLA-matched IGKV3-20-positive tumor cell lines (162).